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ABSTRACT 
 
Background  
Cognitive Stimulation Therapy (CST) is effective and cost-effective for people 
with mild-to-moderate dementia when delivered bi-weekly over seven weeks.  
Aims To examine whether longer-term (maintenance) CST is cost-effective 
when added to usual care.  
Methods  
Cost-effectiveness analysis within multicentre, single-blind, pragmatic 
randomised controlled trial; subgroup analysis for people taking 
acetylcholinesterase inhibitors (ACHEIs). 236 participants with mild-to-
moderate dementia received CST for seven weeks. They were randomised to 
either weekly maintenance CST added to usual care or usual care alone for 24 
weeks.  
Results  
Although outcome gains were modest over 6 months, maintenance CST 
appeared cost-effective when looking at self-rated quality of life as primary 
outcome, and cognition (MMSE) and proxy-rated quality-adjusted life years as 
secondary outcomes. CST in combination with ACHEIs offered cost-
effectiveness gains when outcome was measured as cognition.   
Conclusions  
Continuation of CST is likely to be cost-effective for people with mild-to-
moderate dementia.   
Trial registration  
Current controlled trials ISRCTN26286067. 
 
 
 
 
 
  
 
INTRODUCTION 
Cognitive Stimulation Therapy (CST) is an evidence-based, group intervention for 
people with mild-to-moderate dementia, involving themed activities to stimulate 
cognitive function. It is both effective and cost-effective when delivered bi-weekly 
over seven weeks.
1-3
 Would continuation of CST for longer generate additional 
advantages? Evidence from a pilot study of continued CST suggested improvements 
in cognitive function.
4
 
A randomised controlled trial found that maintenance CST (MCST), delivered weekly 
for 24 weeks (plus usual care), improved patient quality of life compared to usual 
care alone.
5
 It also found that MCST improves cognition for people with dementia 
taking acetylcholinesterase inhibitor medication (ACHEIs). Given intensifying 
pressure on health and social care resources, a key question facing commissioners – 
and one that was recently posed by the National Institute for Health and Care 
Excellence – is whether cognitive stimulation is also cost-effective.
6
 
 
METHODS 
Centres 
Eighteen centres were recruited in London, Essex and Bedfordshire: nine care homes 
and nine community centres (day centres, community mental health teams and 
voluntary organisations). Another three centres were approached: one refused and 
two were excluded because they had insufficient participants meeting inclusion 
criteria. The study has received ethical approval by the Barking & Havering Local 
Research Ethics Committee, reference number: 08/H0702/68 in October 2008.  
Participants  
Participants were eligible for inclusion if they met DSM–IV criteria for dementia;
7
 
scored between 0.5 and 2 (mild-to-moderate) on the Clinical Dementia Rating 
(CDR);
8
 could communicate in English; could see and hear well enough to participate 
in CST; did not have major physical illness or disability (e.g. urinary tract infection, 
delirium or stroke) which could affect participation; or have diagnosed learning 
disability. 
Design 
Participants completed seven weeks of standard CST (14 twice-weekly sessions of 
45-minutes), and were then immediately entered into a single-blind, multi-centre, 
pragmatic randomised controlled trial comparing MCST added to usual care with 
usual care alone. There was no modification in design or eligibility criteria from the 
study protocol.
9
 
Randomisation 
Participants were randomised to either the intervention group receiving weekly 
MCST for 24 weeks in addition to usual care or the control group receiving usual care 
alone.
5
 While usual care did not include any intervention similar to MCST, care 
offered to participants varied between centres. Participants were randomised in 
equal proportions after stratifying for centre, whether ACHEI was prescribed, and 
  
previous CST group. Data storage and transfer were performed to avoid 
contamination. The nature of the intervention precluded blinding of participants, but 
researchers conducting interviews and the statistician analysing outcomes were 
blind to group assignment. Researchers conducting the economic evaluation were 
not blind to assignment. 
Outcome measures 
Participants were assessed at baseline (prior to randomisation), after 3 months 
(intermediate end-point) and after 6 months (primary end-point).  
There were two primary outcomes: 
• cognition measured by ADAS-Cog (Alzheimer’s Disease Assessment Scale-
Cognition subscale): lower scores reflect better cognition;
10
   
• quality of life measured by QoL-AD (Quality of Life-Alzheimer’s Disease scale): 
higher scores reflect better quality of life.
11
 
Secondary outcomes were: 
• Mini-Mental State Examination (MMSE): higher scores reflect better cognition;
12
 
• Neuropsychiatric Inventory (NPI): lower scores reflect better behaviour;
13
 
• ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living 
Inventory): higher scores reflect greater ability in activities of daily living (ADLs);
14
 
• DEMQOL, a dementia-specific quality of life scale completed by participants (self-
report), family carers or care centre workers (proxy): higher scores indicate 
better quality of life;
15
 
• proxy version of QoL-AD, completed by family carers or care centre workers: 
higher scores reflect better quality of life;
11
 
• EQ-5D-3L, a generic health-related quality of life measure completed by 
participants (self-report), family carers or care centre workers (proxy).
16
 
Utility values were calculated from both generic and dementia-specific quality of life 
measures) to compare gain in quality-adjusted life years (QALYs) using both 
participant-reported and proxy-reported measures. QALYs were calculated from EQ-
5D and Proxy EQ-5D using societal weights - York A1 Tariff
17
 –by combining ratings 
on mobility, self-care, usual activities, pain/discomfort, and anxiety and depression 
domains to calculate utility values. QALYs were also calculated from dementia-
specific measures (DEMQOL-U and DEMQOL-PROXY-U) using an algorithm based on 
societal weights.
18
 QALYs were calculated by ‘area under the curve’ analysis, with 
linear interpolation between assessment points.  
Previous findings
19
 suggest that a difference in score of 1.4 points on the 
MMSE can be considered ‘minimum clinically important’. We could not find 
suggestions for clinically important differences on the other measures.  
Resource use and cost measures 
The Client Service Receipt Inventory (CSRI)
20
 was adapted to capture data on all 
health and social care services used in the previous 3 months by participants and 
inputs from unpaid family and other carers. It was completed with family carers or 
centre care workers three times (at randomisation, 3-months and at 6-months). 
Unit costs reflected long-run marginal opportunity costs, taken from the PSSRU 
compendium for 2011.
21 
We discounted at 3.5% for items providing benefit for more 
  
than one year, such as equipment or adaptations. Medication costs came from the 
British National Formulary.
22
 Costs for equipment and adaptations came from 
market sources. Where necessary, unit costs were adjusted to 2011 prices using the 
Consumer Price Index.  
Calculating the cost of MCST itself took into account the one-day training course for 
facilitators (averaging £1.50 per subsequent MCST session, assuming skills acquired 
lasted 5 years), material and equipment used at each session (£1 per MCST session) 
and costs of the two co-facilitators (one researcher, costing £130 per session; one 
care worker, costing £25 per session; the difference is due to preparation and travel 
time). Transport costs were added for participants who travelled to community 
centres for sessions and requested travel refunds (average £1.44 per person per 
session).  
Average total cost per MCST session was £157.46 in care homes and £158.90 
in community centres. Average number of participants per session was five. 
Cost-effectiveness analyses 
The main cost-effectiveness analyses were conducted from a health and social care 
perspective. Further analyses added costs for unpaid carer time (societal 
perspective). The primary economic evaluation measured effectiveness by, in turn, 
each primary outcomes as stated in the analysis plan (ADAS-Cog, QoL-AD). These 
analyses show the additional cost to the health and social care system of achieving a 
one-point difference in each outcome from adding MCST to usual care.  
Secondary economic evaluations were cost-utility analyses, again from each 
perspective, using utilities computed first from EQ-5D and Proxy EQ-5D, and then 
from DEMQOL and Proxy DEMQOL. These secondary analyses show the cost of 
achieving one additional QALY from adding MCST to usual care.  
We also conducted cost-consequences analyses, looking at other secondary 
outcomes (MMSE, ADCS-ADL, proxy QoL-AD) alongside costs. 
There were four potential results from each cost-effectiveness analysis: 
(i) MCST is less costly and more effective than usual care: the decision-maker 
would be attracted to MCST; 
(ii) MCST is more costly and less effective than usual care: the decision-maker 
would be unlikely to recommend, commission or deliver MCST; 
(iii) MCST is less costly but less effective than usual care; and 
(iv) MCST is more costly and more effective than usual care. 
If MCST is less costly and more effective than usual care, or is more costly and less 
effective, then advice to the decision-maker is generally straightforward, although 
measurement error generates some uncertainty. However, if MCST is cheaper but 
less effective, or if MCST is more expensive but also more effective, the decision-
maker must weigh up the outcome and cost differences; the decision will depend on 
the value attached to differences in outcome. In these circumstances we calculate 
the incremental cost-effectiveness ratio (ICER): 
ICER= ΔC /ΔE, 
where ΔC is difference in mean costs between MCST and usual care, and ΔE is mean 
difference in outcome.  
  
ICERs were estimated with the Seemingly Unrelated Regression (SUR) model using 
STATA. Each cost and outcome measure in turn was included in a bivariate system 
that implemented a regression on treatment allocation (MCST or usual care), 
controlling for participant age at baseline, gender, ethnicity, marital status, whether 
or not taking ACHEIs, CDR score at baseline, having a staff (paid) or family (unpaid) 
carer, centre type (community or care home) and centre (location). Cost equations 
also controlled for cost in the 7-week period prior to baseline (obtained by 
standardising 3-month retrospective baseline data), and each outcome equation 
controlled for the corresponding measure at baseline. Multiple imputation was used 
for missing data.
23
 Incremental cost and outcome coefficients and their correlation 
were estimated with 1000 bootstrap replications to address possible skewness. 
Using a series of hypothetical values for willingness-to-pay (λ) for one additional unit 
of outcome (e.g. a one-point difference in ADAS-Cog), net-benefits (NB) were 
calculated as: 
NB=λ*ΔE- ΔC 
The range of willingness-to-pay values was £0 to £6,000 for all outcome measures 
except the QALY (£0 to £100,000). Resultant net-benefit values were used to plot 
cost-effectiveness acceptability curves (CEACs), showing the probability that MCST is 
a cost-effective addition to usual care. Probability values were derived from the 
normal cumulative distribution of net-benefits. 
An advantage of using the SUR method is a gain in efficiency compared to ordinary 
least squares regression methods.
24
 
In additional subgroup analyses, we examined whether there was complementarity 
between MCST and use of ACHEI medications by adding an interaction term to the 
regressions.  
Sensitivity analysis 
We explored a societal perspective rather than health and social care perspective: 
we attached a cost to unpaid care time assuming an opportunity cost approach, with 
each hour of unpaid care set equal to national minimum wage (£6.00 per hour), 
which could represent the opportunity cost to carers of providing support, assuming 
they could alternatively be in employment.  
A further sensitivity analysis examined cost-effectiveness after adjusting intervention 
costs to more closely resemble those expected outside a trial. The intervention cost 
would be lower, since MCST would be delivered by two members of staff in the care 
setting (costing £25 per session), with one taking 30 minutes to plan the session, an 
additional cost of £12.50 per session). It is also expected that staff will train for the 
intervention by reading the Maintenance CST manual
5
 as opposed to receiving face-
to-face training, as in the main analysis, eliminating the training cost component. In 
this scenario, average total cost per MCST session is £63.78 in care homes and 
£65.22 in community centres (less than half the cost in the main analysis).  
However, we cannot estimate the impact that these changes would have on the 
outcomes from CST, and so adjusting costs down can only be a partial sensitivity 
analysis.  
 
  
RESULTS 
Participant characteristics 
Data were collected for 236 people at baseline, 218 at 3 months and 199 at 6 
months. Randomisation produced relatively well-balanced samples: there was a 
slight imbalance with regards to marital status.
5
 
Outcomes 
At 6 months, self-rated quality of life measured by QoL-AD was higher for the MCST 
group than for controls, but there was no inter-group difference in cognition 
measured (ADAS-Cog or any secondary outcomes. At 3 months, there were no inter-
group differences on the two primary outcomes, but the MCST group had 
significantly better proxy-rated quality of life (both QoL-AD and DEMQOL) and ADLs 
(ADCS-ADL).
5
  
Service use 
The groups are quite balanced at baseline in relation to service utilisation (Table 1), 
although the usual care group make more use of residential services, and 
symmetrically less use of community services. This gap in residential care use 
widened slightly post-baseline. This inter-group difference was not a randomisation 
failure, but a consequence of sample attrition: individuals in the intervention group 
were less likely to drop out of the study if living in the community and more likely to 
drop out if living in a care-home. It may be that individuals in the community 
received more support from their family carers to participate. 
Over the study period there were few changes in service use patterns, except that 
both groups used more hospital services.  
Costs 
Cost of MCST itself averaged £623 per participant. Looking across all health and 
social care service costs, residential care was the single largest single item (Table 2). 
Consistent with service use patterns, average residential care costs looked slightly 
higher in the control than intervention group because slightly more people in the 
usual care-only group were living in care homes, although mean difference was not 
statistically significant. In fact, the only significant cost difference between MCST and 
usual care-only groups was for medications (at baseline only).  
Total health and social care costs over 6-months were slightly but not significantly 
lower for the MCST group (£11,306 vs. £11,440). However, this comparison does not 
adjust for baseline covariates, in particular that the MCST group had slightly lower 
costs than the usual care-only group prior to baseline. The cost-effectiveness 
analyses adjusted for these covariates, showing that the intervention group was 
more costly than the control group (see below).  
Cost-effectiveness (at 6 months) 
By 6-months, and after adjustment for baseline covariates, participants receiving 
MCST plus usual care had slightly but not significantly higher health and social care 
costs than participants receiving usual care alone. The adjusted inter-group cost 
difference ranges between £401 and £518 (Table 3) depending on the outcome 
being analysed (because this affects baseline measures used in statistical 
adjustment).  
  
Combining costs and outcomes we generate the ICERs (Table 3). Mean cost per 1-
point difference on QoL-AD was £266. Looking at the CEAC for this outcome, the 
probability that MCST would be seen as cost-effective is 90% at willingness-to-pay of 
about £1,400 (Figure 1). There are no established willingness-to-pay thresholds for 
QoL-AD against which to compare this finding, but for a 1-point difference on a 40-
point scale, a cost of only £1,400 looks modest.  
Based on previous studies,
2
 the effect size of ‘standard’ CST on QoL-AD scale is 0.4 
SD, which is a modest increment. In this study the difference at follow-up for MCST 
was 1.78 points (0.34 SD). A 2-point difference in QoL-AD can be considered clinically 
significant, and costs only £2,800 to achieve. 
For ADAS-Cog, the probability that MCST would be seen as cost-effective was low 
across all willingness-to-pay values (Figure 2). 
Although there was no significant inter-group difference on the MMSE, the cost-
effectiveness analyses suggest that MCST would be a cost-effective addition to usual 
care at low willingness-to-pay thresholds. Howard et al.
19
 have suggested that a 
difference of 1.4 on MMSE is clinically significant; the mean cost of achieving this 
difference through MCST is £781. 
When QALYs were measured using proxy EQ-5D ratings, mean ICER was £26,835; 
from the CEAC the probability that MCST would be cost-effective was 40% at the 
£20,000 threshold associated with NICE recommendations, and 54% at the £30,000 
threshold.
25
 For none of the other QALY measures was there evidence that MCST 
would be cost-effective (Table 3).  
Interaction with use of ACHEIs  
Examination of the impact of ACHEI use on the effectiveness of MCST found no 
significant differences in outcomes except MMSE, adjusting for baseline covariates.
5
 
Participants taking ACHEI medications randomised to MCST had the smallest decline 
in cognitive functioning; participants taking ACHEIs randomised to usual care only 
had the largest.  
Total health and social care (including intervention) costs over 6 months were £7,248 
for participants randomised to MCST taking ACHEIs, £13,482 for participants 
randomised to MCST not taking ACHEIs, £9,256 for the usual care group taking 
ACHEIs, and £12,381 for the usual care group not taking ACHEIs. On average, 
individuals not taking ACHEIs made greater use of health and social care resources. 
An interaction term for MCST and ACHEI in the SUR regressions showed a positive 
interaction between MCST and ACHEI for MMSE, significant at 3 months 
(bootstrapped coefficient=2.39, p=0.06) and almost significant at 6 months 
(bootstrapped coefficient=2.63, p=0.11). Mean ICERs are reported in Table 3. By 
reference to self-reported and proxy-rated EQ-5D, MCST in combination with ACHEI 
appears more cost-effective than ACHEI treatment with usual care, with mean ICERs 
below the NICE £20,000 threshold.
25
 
Sensitivity analyses 
We repeated the analyses from a societal perspective. When looking at unadjusted 
differences, unpaid carer costs were not significantly higher at 5% level for the MCST 
group compared to the usual care-only group over 6 months (Table 2). Adjusted 
  
differences were not significant for most aggregates, with the exception of pre-
baseline unpaid carer and total costs. 
Estimated ICERs from the societal perspective show that usual care dominated MCST 
when looking at ADAS-Cog (Table 3). For QoL-AD, the estimated ICER was £643 over 
6 months.  Assuming MCST costs more closely resembling those in standard practice 
showed that MCST was more cost-effective than usual care (Table 3). In particular, 
the ICER for QoL-AD decreased to £68 over 6 months. Among secondary outcomes, 
the ICER was £143 for each 1-point difference on MMSE and £126 for each 1-point 
difference on ADCS-ADL. Cost per QALY was quite low: £6,841 when generated from 
proxy-rated EQ-5D and £7,666 from proxy-rated DEMQOL over 6 months.  
 
DISCUSSION  
Summary 
Previous studies show that CST is effective in improving cognition and quality of life
2
  
and cost-effective.
3
 CST is endorsed in NICE clinical guidelines (NICE-SCIE 2006). 
Orrell et al.
5
 showed that people with dementia receiving CST who then continue 
with the therapy for another 24 weeks had better quality of life at 6-months 
compared to people who instead continued with usual care. Adjusting for baseline 
covariates, health and social care costs for MCST were slightly although not 
statistically significantly higher than for usual care-only.  
The two primary outcomes for the trial were quality of life measured by QoL-AD and 
cognition measured by ADAS-Cog. On the former, MCST was cost-effective compared 
to usual care at 6 months; on the latter, MCST was not cost-effective at 6 months.  
Four of eight secondary outcomes measures in the study were QALY measures. 
Results were mixed. MCST was cost-effective for cognition measured by MMSE, 
ability in ADLs, and proxy-rated quality of life measured by proxy Qol-AD and proxy 
DEMQOL. For QALYs calculated from proxy EQ-5D, MCST was also cost-effective 
against the NICE threshold of £30,000 per QALY.  For the remaining three QALY 
outcomes, MCST was not cost-effective at 6 months.   
Sensitivity analyses conducted from a societal perspective again produced mixed 
cost-effectiveness findings.  
Subgroup analyses found that combining MCST and ACHEI was more cost-effective 
than ACHEI and usual care by reference to a number of outcomes, including cost per 
QALY.  
Comparison with other studies 
There is only one previous economic evaluation of CST: CST delivered twice-weekly 
over 7 weeks was cost-effective, with mean cost per incremental difference in MMSE 
of £75, and mean cost per incremental difference in QoL-AD of £23 (from a health 
and social care perspective).
3
 In the present study, cost per incremental difference 
on these same two measures at 6-months, even allowing for price inflation over 
time, was much higher (£558 and £266, respectively). The earlier study also found a 
significant improvement in cognition measured by ADAS-Cog; there was no similar 
difference in our new study. These results may arise because the usual care group in 
the current study continued to experience benefits from their initial seven weeks of 
  
CST. Although based on relatively few studies, the Cochrane review of cognitive 
stimulation
2
 suggested that benefits in terms of cognition were evident, for example, 
3 months after the end of CST. 
Although there have been numerous economic studies of medications for treating 
dementia,
26
 none has looked at interactions with CST to allow comparison with the 
present trial. 
Strengths and limitations 
Orrell et al.
5
 discuss a number of strengths and limitations of the trial. One limitation 
of the economic analysis is that unpaid carers or care staff who completed proxy 
ratings were not blind to treatment allocation, opening up the risk of detection bias. 
Some cost-effectiveness advantages found for MCST, at 3 and 6 months, were based 
on proxy ratings. 
Studies that compare usual care with an intervention added to usual care, and which 
recruit across multiple sites, have the advantage that ‘usual care’ potentially reflects 
a range of treatment and care arrangements, making it easier to generalise findings 
to other contexts. On the other hand, variation in what constitutes ‘usual care’ 
between sites may affect outcomes and costs. However, there was no site-related 
imbalance in the randomisation procedure in this pragmatic trial, and the cost-
effectiveness analyses adjusted for site.  
A common limitation of economics studies in the dementia field is uncertainty 
surrounding the costing of unpaid care. It is inherently difficult to measure time 
spent supporting someone with dementia, and there are various ways to attach 
costs to that time. These uncertainties only affect analyses from a societal 
perspective.  
The EQ5D and DEMQOL-based QALY measures do not provide consistent cost-
effectiveness findings. This is not unexpected since EQ-5D is a generic quality of life 
indicator, while DEMQOL is dementia-specific. Previous studies have shown that for 
people with dementia self-rated and proxy quality of life measures often have low 
levels of overall agreement and therefore cannot be assumed to substitute for each 
other (e.g. Arons et al.
27
). For these reasons, we have reported results using both 
approaches. 
Implications for policy and practice 
The importance of promoting new strategies for improving care and support for 
people with dementia was highlighted in the formal declaration from the G8 
Dementia Summit, December 2013: ‘We [Health and Science Ministers] … call for 
greater innovation to improve the quality of life for people with dementia and their 
carers while reducing emotional and financial burden.’ Our new study of the cost-
effectiveness of maintenance cognitive stimulation therapy contributes modestly to 
the evidence base.  
The economic case for continuing CST beyond an initial 7-week twice-weekly 
programme is mixed. While maintenance CST did not increase health and social care 
costs (or costs of unpaid care), outcome gains were modest over 6-months. On 
economic grounds, a case could be argued for adding MCST to usual care if the 
outcomes of primary concern are self-rated quality of life, interviewer-rated 
cognition (measured by MMSE), or proxy-rated QALYs (from the EQ-5D). But the 
  
economic case for MCST cannot be made by reference to other outcomes: it was not 
that MCST participants fared less well as assessed by those other measures, but that 
the small (even if insignificant) increase in costs associated with MCST did not appear 
to be justified by the outcomes. Following a research stream recommended by NICE, 
we found that combining MCST with ACHEI medication has economic advantages 
over ACHEI with usual care alone. Moreover, MCST looks more cost-effective than 
usual care when costs are used that more closely resemble those in standard 
practice. Rolling out MCST more widely (beyond the research context) might 
therefore have economic advantages, although we do not know from this study 
whether outcomes would be different. 
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Table 1: Use of services, equipment, adaptations and medications by allocation 
group and time-point 
 
Variable 
Pre-baseline (7 weeks)  
Control  Intervention 
Residential care 56 54% 56 49% 
Hospital services 24 23% 32 28% 
Day-services 85 82% 98 86% 
Equipment and 
adaptations 13 13% 17 15% 
Community services 36 35% 53 46% 
Medications 97 93% 110 96% 
N 104 100% 114 100% 
Variable 
1-3 months 
Control  Intervention 
Residential care 56 54% 55 48% 
Hospital services 39 38% 39 34% 
Day-services 84 81% 95 83% 
Equipment and 
adaptations 17 16% 15 13% 
Community services 44 42% 56 49% 
Medications 102 98% 109 96% 
N 104 100% 114 100% 
Variable 
4-6 months 
Control  Intervention 
Residential care 49 53% 49 46% 
Hospital services 30 32% 35 33% 
Day-services 77 83% 92 87% 
Equipment and 
adaptations 11 12% 17 16% 
Community services 37 40% 52 49% 
Medications 88 95% 102 96% 
N 93 100% 106 100% 
 
  
  
Table 2: Health and social care and societal perspective costs, including 
intervention costs, by allocation group and time-point 
  
Control  Intervention  
Difference between the 
groups 
Mean  (SD) Mean (SD) 
Mean 
diff. 
p-
value 
Adjusted p-
value 
Health and social care perspective 
Pre-baseline (7 weeks) 
– N 
104 114       
Residential care 
2688.
6 
(2682
.5) 
2380.
1 
(2643
.6) 
308.5 0.4 0.33 
Hospital services 84.7 
(274.
2) 
73.4 
(215.
2) 
11.3 0.73 0.65 
Day-services 172.6 
(325.
3) 
193.7 
(389.
7) 
-21.1 0.66 0.86 
Equipment & 
adaptations 
2 (7.3) 2.3 (7.6) -0.3 0.76 0.73 
Community services 185.4 
(338.
8) 
218.9 
(310.
4) 
-33.5 0.44 0.72 
Medications 98.4 (88.3) 127.4 (97) -29 0.02 0.02 
CST intervention 174.2 (68.1) 164.2 (54.7) 10 0.23 0.51 
Total costs 
3405.
9 
(2407
) 
3160 
(2383
.7) 
245.9 0.45 0.36 
1-3 months – N 104 114       
Residential care 
4563.
9 
(4513
.5) 
4072.
2 
(4564
.8) 
491.7 0.42 0.36 
Hospital services 164.4 
(425.
4) 
169.3 
(433.
2) 
-4.9 0.93 0.88 
Day-services 401.6 
(920.
6) 
440.1 
(894.
7) 
-38.5 0.75 0.82 
Equipment & 
adaptations 
8.8 (39.6) 8.8 (44.1) 0 1 0.94 
Community services 509.7 
(872.
6) 
494.1 
(741.
8) 
15.6 0.89 0.14 
Medications 178.6 
(146.
1) 
197.2 
(147.
5) 
-18.6 0.34 0.45 
MCST intervention - - 299.9 
(140.
4) 
- - - 
Total costs 
5826.
9 
(4083
.5) 
5681.
5 
(4062
.4) 
145.4 0.79 0.14 
4-6 months – N 93 106       
Residential care 
4591.
1 
(4615
.7) 
4023.
1 
(4571
.9) 
568 0.38 0.4 
Hospital services 142.5 (386) 147.7 
(407.
9) 
-5.2 0.93 0.95 
Day-services 280.4 
(623.
2) 
421.1 
(991.
7) 
-140.7 0.22 0.33 
Equipment & 
adaptations 
10.9 (45) 6 (16.3) 4.9 0.33 0.29 
Community services 473.3 
(847.
6) 
471.6 
(740.
2) 
1.7 0.99 0.09 
Medications 193.8 (163. 194.8 (140. -1 0.97 0.94 
  
5) 4) 
MSCT intervention - - 322.5 
(224.
5) 
- - - 
Total costs 5692 
(4132
.7) 
5586.
8 
(4033
.7) 
105.2 0.86 0.53 
1-6 months – N 93 106       
Residential care 
9116.
4 
(8930
.7) 
8157.
8 
(9092
) 
958.6 0.45 0.94 
Hospital services 268.7 
(497.
8) 
302.2 
(569.
4) 
-33.5 0.66 0.7 
Day-services 696.1 
(1471
) 
858.5 
(1646
) 
-162.4 0.47 0.77 
Equipment & 
adaptations 
20.3 (84.2) 14.1 (52.9) 6.2 0.54 0.37 
Community services 963.4 
(1662
.1) 
958.2 
(1397
.2) 
5.2 0.98 0.09 
Medications 375.1 
(289.
6) 
391.2 
(269.
5) 
-16.1 0.68 0.9 
MSCT intervention - - 623.8 
(341.
4) 
- - - 
Total costs 
1144
0 
(7971
.6) 
1130
5.7 
(7873
) 
134.3 0.91 0.24 
Societal perspective 
Pre-baseline (7 weeks) 
– N 
104 114       
Total health and social 
care costs 
3405.
9 
(2407
) 
3160 
(2383
.7) 
245.9 0.45 0.36 
Unpaid carer costs 680.3 
(1126
.6) 
1053.
5 
(1659
.8) 
-373.2 0.05 0.03 
Total societal costs 
4086.
2 
(1982
.2) 
4213.
5 
(2036
.3) 
-127.3 0.64 0.02 
1-3 months – N 104 114       
Total health and social 
care costs 
5826.
9 
(4083
.5) 
5681.
5 
(4062
.4) 
145.4 0.79 0.14 
Unpaid carer costs 1655 
(3163
.8) 
2572.
2 
(3894
.2) 
-917.3 0.05 0.1 
Total societal costs 
7481.
9 
(3517
.2) 
8253.
7 
(3549
.8) 
-771.8 0.11 0.02 
4-6 months – N 93 106       
Total health and social 
care costs 
5692 
(4132
.7) 
5586.
8 
(4033
.7) 
105.2 0.86 0.53 
Unpaid carer costs 
2053.
1 
(3666
.7) 
2820.
4 
(4228
.2) 
-767.3 0.17 0.78 
Total societal costs 
7745.
2 
(3633
) 
8407.
2 
(3680
.9) 
-662.1 0.2 0.56 
1-6 months – N 93 106       
Total health and social 
care costs 
1144
0 
(7971
.6) 
1130
5.7 
(7873
) 
134.3 0.91 0.24 
Unpaid carer costs 
3752.
4 
(6416
.2) 
5504.
4 
(8089
.7) 
-1752 0.08 0.34 
Total societal costs 
1519
2.4 
(6294
.1) 
1681
0.1 
(6757
.7) 
-1617.7 0.08 0.12 
  
 
 
Table 3: Incremental cost-effectiveness ratios  over 1-6 month   
 
 
Incremental cost Incremental effect 
ICER 
  
(£, 2010/11) Mean [95% 
bootstrap CI] 
Mean [95% 
bootstrap CI] 
MCST vs. TAU (Health and social care perspective) 
1-6 months       
ADAS-Cog 473.89 [-315.45, 1263.23] -0.65 [-4.08, 2.77] 
Usual care 
dominant 
QoL-AD 473.46 [-315.61,  1262.53] 1.78 [-0.39,  3.95] 266 
MMSE  474.01 [-316.15,  1264.17] 0.85 [-0.48,  2.18] 558 
ADCS-ADL 471.57 [-317.67,  1260.81] 0.95 [-2.50,  4.39] 498 
Proxy QoL-AD 472.70 [-314.60,  1260.01] 0.07 [-1.63,   1.76] 7,050 
Proxy DEMQOL 472.31 [-338.46,  1283.07] 1.13 [-2.48,  4.74] 419 
QALY (EQ-5D) 474.81 [-314.38,  1263.99] 
0.0013 [-0.0200,  
0.0223] 
365,276 
QALY (Proxy EQ-
5D) 
473.60 [-315.48,  1262.68] 
0.0176 [-0.0050,  
0.0403] 
26,835 
QALY (DEMQOL) 518.39 [-346.60,  1383.39] 
0.0039 [-0.0092,  
0.0170] 
132,539 
QALY (Proxy 
DEMQOL) 
401.52 [-441.99,  1245.04] 
0.0062 [-0.0049,   
0.0173] 
64,785 
ACHEIs/MCST vs. ACHEIs 
1-6 months       
ADAS-Cog 465.57 [-781.21, 1712.35] 0.74 [-7.86, 9.34] 630 
QoL-AD 466.17 [-780.11, 1712.45] 0.78 [-3.76, 5.33] 597 
MMSE 465.55 [-781.46, 1712.55] 2.63 [-0.97, 6.22] 177 
ADCS-ADL 468.22 [-777.54, 1713.97] 1.47 [-7.63, 10.57] 319 
Proxy QoL-AD 466.90 [-779.24, 1713.03] -0.37 [-4.90, 4.16] 
ACHEIs 
dominant 
Proxy DEMQOL 468.75 [-779.83, 1717.33] 4.81 [-7.11, 16.74] 97 
QALY (EQ-5D) 464.72 [-783.02, 1712.46] 
0.0257 [-0.0178, 
0.0692] 
18,068 
QALY (Proxy EQ-
5D) 
465.88 [-780.99, 1712.75] 
0.0262 [-0.0190, 
0.0714] 
17,787 
QALY (DEMQOL) 494.01 [-819.14, 1807.17] 
0.0004 [-0.0498, 
0.0505] 
1,308,421 
QALY (Proxy 
DEMQOL) 
360.43 [-913.85, 1634.72] 
0.0025 [-0.0304, 
0.0354] 
143,979 
MCST vs. TAU (Societal perspective) 
1-6 months       
ADAS-Cog 1143.07 [-336.50,    2622.63] -0.64 [-4.06,     2.79] 
Usual care 
dominant 
QoL-AD 1143.14 [-335.45,    2621.73] 1.78 [-0.40,    3.95] 643 
MMSE 1145.46 [-333.57,    2624.50] 0.85 [-0.48,    2.18] 1,350 
ADCS-ADL 1137.30 [-344.55,    2619.15] 0.98 [-2.50,    4.46] 1,162 
Proxy QoL-AD 1138.41 [-340.40,    2617.23] 0.07 [-1.62,    1.76] 15,258 
  
Proxy DEMQOL 1137.73 [-356.55,    2632.02] 1.13 [-2.48,    4.74] 1,004 
QALY (EQ-5D) 1145.72 [-332.72,    2624.16] 
0.0013 [-0.0197,    
0.0222] 
882,801 
QALY (Proxy EQ-
5D) 
1142.78 [-338.64,    2624.20] 
0.0176 [-0.0050,    
0.0403] 
64,842 
QALY (DEMQOL) 1574.56 [-176.49,      3325.60] 
0.0039 [-0.0092,    
0.0171] 
400,993 
QALY (Proxy 
DEMQOL) 
1259.07 [-252.22,    2770.36] 
0.0061 [-0.0050,    
0.0173] 
205,079 
MCST vs. TAU (Implementation of the intervention "in practice") 
1-6 months       
ADAS-Cog 121.04; [-669.32, 911.39] -0.65; [-4.08, 2.77] 
Usual care 
dominant 
QoL-AD 120.56;  [-669.51,  910.64] 1.78;   [-0.39,  3.95] 68 
MMSE 121.20;  [-669.91,  912.31] 0.85;   [-0.48,  2.18] 143 
ADCS-ADL 118.81;   [-671.40,  909.01] 0.95;   [-2.50,  4.39] 126 
Proxy QoL-AD 119.81;   [-668.30,  907.91] 0.07;   [-1.63,   1.76] 1,786 
Proxy DEMQOL 117.07;   [-693.74,  927.88] 1.13;   [-2.48,  4.74] 104 
QALY (EQ-5D) 122.08;   [-668.07,  912.23] 
0.0013;   [-0.0200,  
0.0223] 
93,912 
QALY (Proxy EQ-
5D) 
120.74;   [-669.30,  910.78] 
0.0176;   [-0.0050,  
0.0403] 
6,841 
QALY (DEMQOL) 162.13;   [-701.89,  1026.15] 
0.0039;   [-0.0092,  
0.0170] 
41,425 
QALY (Proxy 
DEMQOL) 
47.51;   [-797.21,  892.24] 
0.0062;   [-0.0049,   
0.0173] 
7,666 
 
 
 
